Int J Curr Pharm Res, Vol 15, Issue 6, 43-49Review Article

COMPREHENSIVE REVIEW OF POST-COVID-19 INFECTIONS: A MULTIFACETED ANALYSIS

VIJAYALAXMI A. SHENDE1*

1Wellness Assessment Centre, Aditya Birla Memorial Hospital, Chinchwad, Pune-411033, Maharashtra, India
*Corresponding author: Vijayalaxmi A. Shende; *Email: drvas21@gmail.com

Received: 20 Aug 2023, Revised and Accepted: 05 Oct 2023

ABSTRACT

This comprehensive review offers a multifaceted analysis of post-COVID-19 infections, encompassing diverse aspects of this evolving health concern. In the realm of symptomatology, we explore both common and rare symptoms observed in individuals recovering from COVID-19, shedding light on the intricacies of post-acute sequelae. Moving forward, we delve into the association between COVID-19 and diabetes along with glucose intolerance, analyzing the incidence of these metabolic conditions in the post-COVID era. Another critical dimension of our analysis is the examination of the potential direct association between COVID-19 and obesity, considering the implications of this relationship on public health. Furthermore, we trace the evolution of treatment strategies across the pandemic's waves, providing a comprehensive review of approaches taken during the 1st, 2nd, and 3rd waves, along with discussions on current government-recommended treatment and management protocols. As we navigate the ongoing challenges presented by post-COVID-19 conditions, this article aims to serve as a valuable resource for healthcare professionals, researchers, and individuals seeking a deeper understanding of the multifaceted nature of these infections and their implications for healthcare and public health strategies. Concluding remarks, this comprehensive review underscores the complex landscape of post-COVID-19 infections, ranging from symptomatology to metabolic associations and treatment strategies. It serves as a vital resource for understanding the multifaceted implications of these conditions on healthcare and public health efforts.

Keywords: Post-COVID-19, Infections, Symptomatology, Diabetes, Obesity

© 2023 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/)
DOI: https://dx.doi.org/10.22159/ijcpr.2023v15i6.4000. Journal homepage: https://innovareacademics.in/journals/index.php/ijcpr

INTRODUCTION

The COVID-19 pandemic, an unprecedented global health crisis, has left an indelible mark on societies and healthcare systems worldwide. As the world grappled with the acute phase of this viral illness, a novel concern emerged: the myriad of post-COVID-19 infections and complications affecting a significant number of survivors [1]. This comprehensive review endeavors to unravel the multifaceted landscape of post-COVID-19 infections, shedding light on diverse aspects and challenges associated with these conditions.

In the wake of the pandemic's initial onslaught, it became increasingly evident that the effects of COVID-19 extend far beyond the acute illness. Many individuals who survived the acute phase found themselves grappling with a range of health issues that persisted long after the virus had been cleared from their systems. These post-COVID-19 infections, characterized by a wide spectrum of symptoms and clinical presentations, pose a complex and evolving challenge to healthcare providers and researchers alike [2].

The first section of this comprehensive review delves into the realm of symptomatology. Here, we embark on a journey to explore the common symptoms observed in post-COVID-19 patients. While some manifestations align with the well-documented acute symptoms of COVID-19, others manifest as unusual and rare clinical presentations, adding to the complexity of post-acute sequelae [3]. Through an in-depth examination of these symptoms, we aim to provide a nuanced understanding of the challenges faced by individuals on their path to recovery.

Beyond symptomatology, this review explores the intricate interplay between COVID-19 and metabolic health. The association between COVID-19 and diabetes, as well as glucose intolerance, comes under scrutiny [4]. We analyze the incidence of these metabolic conditions in the post-COVID era, shedding light on the implications of viral infections on long-term metabolic health.

A critical dimension of our analysis centers on the potential direct association between COVID-19 and obesity, a pressing concern given the global rise in obesity rates [5]. We examine the existing evidence to discern whether COVID-19 and obesity share a symbiotic relationship, and we assess the broader public health implications of this association.

Furthermore, as the pandemic has evolved, so too have the treatment strategies employed to manage COVID-19 cases. This review provides a comprehensive overview of the evolving approaches to treatment during the pandemic's different waves, spanning the 1st, 2nd, and 3rd waves [6]. We also engage in discussions surrounding current government-recommended treatment and management protocols, recognizing the dynamic nature of healthcare responses in the face of a continually evolving virus.

To sum up, this comprehensive review underscores the multifaceted nature of post-COVID-19 infections, encompassing symptomatology, metabolic associations, and evolving treatment strategies. As healthcare systems worldwide grapple with the challenges posed by these conditions, this review serves as a valuable resource for healthcare professionals, researchers, and individuals seeking to comprehend the complex and evolving landscape of post-COVID-19 infections and their implications for healthcare and public health strategies.

Symptomatology

"Symptomatology" refers to the comprehensive examination and analysis of the symptoms experienced by individuals after recovering from the acute phase of COVID-19. This section aims to provide a detailed account of the various physical and psychological symptoms that persist or emerge in the post-recovery period. It encompasses the exploration of common symptoms commonly observed in post-COVID-19 patients, as well as the investigation of rare and unusual symptoms reported in specific cases. By delving into symptomatology, this review seeks to offer a deeper understanding of the health challenges faced by COVID-19 survivors beyond the acute phase of the disease.

Exploration of common symptoms observed in post-COVID-19 patients

The COVID-19 pandemic has disrupted lives across the globe, with millions of individuals falling ill and experiencing the acute phase of the disease. As the world grapples with the immediate challenges posed by the virus, a growing concern has emerged the multitude of symptoms and health complications that persist or arise in individuals who have recovered from the acute phase of COVID-19. These post-COVID-19 symptoms, often referred to as "long COVID" or "post-acute sequelae of SARS-CoV-2 infection" (PASC), have drawn increasing attention from healthcare professionals, researchers and the affected individuals themselves [7].

This comprehensive review delves into the exploration of common symptoms observed in post-COVID-19 patients, shedding light on the multifaceted and often challenging landscape of long-lasting COVID-19 effects. We aim to provide a detailed examination of the symptoms that plague many survivors, understanding their impact on health, daily life, and the healthcare system. By comprehensively exploring these common post-COVID-19 symptoms, we seek to enhance our understanding of the long-term consequences of the disease and inform strategies for management and support.

Common post-COVID-19 symptoms

One of the most frequently reported symptoms among post-COVID-19 individuals is debilitating fatigue. This fatigue often persists for weeks or months after the acute phase of the disease has passed. Survivors describe it as an overwhelming and unrelenting exhaustion that affects both physical and mental well-being. Fatigue can interfere with daily activities, making it challenging for individuals to return to work, engage in physical exercise, or perform routine tasks [8]. The exact mechanisms behind COVID-19-related fatigue are not fully understood, but factors such as inflammation, immune dysregulation, and the virus's direct impact on tissues and organs may contribute to this persistent symptom [8]. Management of post-COVID-19 fatigue typically involves a gradual increase in physical activity, along with rest and pacing strategies to prevent exacerbation.

Another prevalent symptom in post-COVID-19 individuals is shortness of breath or dyspnea. Survivors often report difficulty in breathing, even with minimal physical exertion [9]. This symptom can be distressing and may limit one's ability to perform simple tasks like climbing stairs or walking. Shortness of breath can persist due to lung damage caused by the virus, inflammation, or the formation of blood clots in the pulmonary vasculature. Rehabilitation and respiratory therapies are essential in managing post-COVID-19 dyspnea [10]. Pulmonary function tests, imaging studies, and oxygen therapy may be employed to evaluate and address lung-related issues. Exercise programs aimed at improving lung capacity and overall cardiovascular health are also beneficial [11].

Cognitive impairment, often described as "brain fog," is a concerning symptom affecting many post-COVID-19 individuals [12]. Survivors report difficulties with concentration, memory, and mental clarity. This cognitive decline can hinder daily tasks, work productivity, and overall quality of life [13]. The causes of post-COVID-19 cognitive impairment are multifactorial, with potential contributions from inflammation, neurological damage, and psychological factors. Cognitive rehabilitation, mental health support, and strategies for managing daily tasks and responsibilities can help individuals regain cognitive function and cope with brain fog. Chest pain and discomfort are prevalent symptoms in post-COVID-19 patients [14]. Survivors may experience a range of sensations, including chest tightness, stabbing pains, or a persistent ache. These symptoms often lead to anxiety and concern about heart-related issues. While some individuals may have underlying cardiac conditions exacerbated by COVID-19, many cases of chest pain are attributed to post-viral inflammation or musculoskeletal issues. Cardiac evaluations, including electrocardiograms and cardiac enzyme tests, are crucial in ruling out heart-related concerns. Pain management, anti-inflammatory medications, and physical therapy may be recommended [15, 16].

COVID-19 has been associated with various gastrointestinal (GI) symptoms during the acute phase of the illness, including diarrhea, nausea, and abdominal pain. These GI symptoms can persist or emerge as new issues in post-COVID-19 individuals. Some survivors report ongoing digestive problems, such as irritable bowel syndrome (IBS)-like symptoms or altered bowel habits [17].

The mechanisms underlying post-COVID-19 GI symptoms are not fully understood but may involve persistent viral shedding in the GI tract or immune-related responses. Management often includes dietary modifications, probiotics, and medications to alleviate specific symptoms [18].

Anosmia, or loss of the sense of smell, and dysgeusia, alterations in taste perception, are hallmark symptoms of COVID-19 during the acute phase of the infection. While these sensory disturbances often resolve in the acute stage, some individuals continue to experience anosmia and dysgeusia for an extended period in the post-COVID-19 phase. These sensory changes can impact one's enjoyment of food and beverages, as well as their ability to detect potentially dangerous odors [19]. Supportive care and strategies to enhance the enjoyment of food are typically recommended.

The psychological toll of COVID-19 extends beyond the acute phase of the illness. Survivors may grapple with mood disorders such as anxiety and depression, often as a result of the stress, isolation, and fear associated with the pandemic [20]. Additionally, the physical symptoms and uncertainties about the future can exacerbate mental health challenges. Addressing the psychological impact of post-COVID-19 life is essential, and mental health services, counseling, and support groups play a critical role in helping individuals cope with these challenges. The exploration of common symptoms observed in post-COVID-19 patients reveals a complex and multifaceted landscape of health challenges faced by survivors.

Investigating rare and unusual symptoms reported in post-COVID-19 cases

The COVID-19 pandemic has evolved into one of the most significant global health crises in recent history. While a substantial portion of infected individuals experience mild to moderate symptoms or recover fully, a growing body of evidence suggests that a subset of COVID-19 survivors continues to grapple with a range of health issues long after the acute phase of the illness has passed. These persistent symptoms, often referred to as "long COVID" or "post-acute sequelae of SARS-CoV-2 infection" (PASC), have garnered significant attention from healthcare professionals, researchers, and the affected individuals themselves [21].

While many long COVID symptoms are well-documented and include fatigue, shortness of breath, and cognitive difficulties, there is an emerging category of rare and unusual symptoms that have been reported in post-COVID-19 cases [22]. These symptoms defy easy categorization and present unique challenges for diagnosis and management. In this comprehensive exploration, we delve into the world of these rare and perplexing manifestations, aiming to shed light on their prevalence, potential mechanisms, and impact on patients' lives.

Gastrointestinal and digestive anomalies are noticed in COVID-19, which primarily presents as a respiratory illness, but its effects on the gastrointestinal (GI) system have become increasingly evident. Common GI symptoms during the acute phase of the disease include nausea, diarrhea, and loss of appetite. However, in post-COVID-19 cases, some individuals report ongoing and peculiar GI issues, such as unexplained weight loss, severe and persistent abdominal pain, and gastrointestinal bleeding. These symptoms often lead to extensive diagnostic investigations, including endoscopies and imaging studies, to uncover the underlying causes. Intriguingly, some long COVID patients with GI symptoms do not exhibit typical markers of GI diseases like inflammatory bowel disease or celiac disease. Research into the mechanisms behind these symptoms is ongoing, with hypotheses ranging from direct viral effects on GI tissues to dysregulation of the gut microbiome due to the initial infection [23, 24].

Neurological Enigmas is an apt term to describe the baffling array of rare and unusual symptoms that have been reported in post-COVID-19 cases. Neurological symptoms are not uncommon in COVID-19 patients, with reports of anosmia (loss of smell) and dysgeusia (altered sense of taste) becoming well-recognized early in the pandemic [25]. However, rare neurological manifestations are now surfacing in post-COVID-19 individuals, leading to substantial concern among clinicians and researchers. Some patients experience episodes of severe and debilitating headaches that differ from migraines or tension-type headaches they may have had before. Others report unexplained muscle twitching, tremors, or even focal seizures. Perhaps most perplexing are the cases of individuals who develop neurological symptoms reminiscent of autoimmune conditions like multiple sclerosis yet without clear evidence of such diseases [26]. Understanding the underlying mechanisms of these neurological symptoms is a complex puzzle. While direct viral invasion of the central nervous system remains a possibility, the contributions of inflammation, immune dysregulation, and post-infectious processes are actively being explored.

Dermatological Dilemmas are explained frequently. Skin manifestations in COVID-19 patients have varied widely, from rashes and hives to COVID toes (pernio-like lesions). In post-COVID-19 cases, certain individuals develop unusual dermatological conditions that continue to baffle dermatologists and researchers. One such condition is "COVID nails," characterized by transverse white lines or ridges that appear on the nails weeks to months after the acute infection. While these nail abnormalities are not painful, they serve as a visible reminder of the virus's lingering effects. Additionally, some long COVID patients develop skin lesions resembling livedo reticularis, a condition characterized by mottled or net-like patterns on the skin, particularly on the extremities [27, 28]. The mechanisms underlying these dermatological manifestations are not entirely understood. Immune-mediated processes, vascular abnormalities, or microcirculatory changes are some of the proposed explanations, but further research is required for definitive answers.

Early in the pandemic, COVID-19 was primarily seen as a respiratory virus. However, it quickly became evident that the virus could have far-reaching effects on the cardiovascular system. While acute cardiac complications like myocarditis and arrhythmias have been documented, rare cardiovascular symptoms have surfaced in post-COVID-19 patients [29]. Individuals experiencing prolonged chest pain, palpitations, or episodes of fainting have sought medical attention. In some cases, comprehensive cardiac evaluations reveal no structural abnormalities or traditional risk factors [30]. These symptoms, which can be severely debilitating, underscore the need for a deeper understanding of COVID-19's impact on the heart and vascular system. Potential mechanisms for these cardiovascular symptoms include ongoing inflammation, autonomic dysregulation, and microvascular dysfunction, but ongoing research is essential to unravel the complexities.

Psychiatric symptoms will work as a Puzzle. The psychological toll of the COVID-19 pandemic is well-documented, with anxiety, depression, and post-traumatic stress symptoms affecting many [31]. However, rare and peculiar psychiatric symptoms have emerged in some post-COVID-19 cases, adding another layer of complexity to the long COVID phenomenon. Patients report experiencing vivid and distressing nightmares, hallucinations, or "brain fog" that significantly impairs their cognitive function. Some individuals describe emotional lability characterized by sudden and unpredictable mood swings [14]. These symptoms often overlap with known psychiatric disorders but occur in individuals with no prior history of such conditions. The relationship between COVID-19 and these psychiatric symptoms is not fully elucidated. Possible mechanisms include direct viral effects on the central nervous system, neuroinflammation, or post-infectious immune responses.

Finally, the spectrum of rare and unusual symptoms reported in post-COVID-19 cases adds complexity to our understanding of the disease's long-term consequences. These enigmatic manifestations span multiple organ systems, from the GI tract to the nervous system, skin, heart, and mind. While they remain relatively uncommon, they underscore the need for continued research into the mechanisms underlying long COVID and the development of effective management strategies. Lastly, healthcare professionals, researchers, and affected individuals alike must collaborate to shed light on these perplexing symptoms, providing support, answers, and hope for those grappling with the lingering effects of COVID-19. As the scientific community delves deeper into these mysteries, it is our hope that rare and unusual symptoms will become less mysterious, offering relief and resolution to those on their long road to recovery.

Association of COVID-19 with diabetes and glucose intolerance

The COVID-19 pandemic has not only posed a global health crisis but has also shed light on the intricate relationship between viral infections and pre-existing health conditions. Among these conditions, diabetes and glucose intolerance have emerged as significant concerns. This introduction explores the association between COVID-19 and diabetes, emphasizing the impact of the virus on individuals with these underlying metabolic conditions.

Analyzing the incidence of diabetes and glucose intolerance in the post-COVID era

The COVID-19 pandemic, initially identified as a respiratory illness, has unveiled a broader spectrum of consequences on human health. Beyond the immediate respiratory impact, this novel coronavirus, known as SARS-CoV-2, has been linked to various other health issues, including metabolic disorders like diabetes and glucose intolerance. As we enter the post-COVID era, understanding the incidence of these metabolic conditions has become increasingly critical.

COVID-19, initially characterized as a respiratory disease, has, over time, revealed its capacity to affect multiple organ systems, including those responsible for glucose metabolism. The intricate interplay between COVID-19 and metabolic disorders, particularly diabetes and glucose intolerance, has raised concerns about the long-term health implications for individuals who have experienced the virus [32].

In the case of the incidence of Post-COVID diabetes, an emerging concern. It is notable observation in the post-COVID era is the emergence of new cases of diabetes. While the link between pre-existing diabetes and severe COVID-19 outcomes is well-established, studies are now reporting an increased risk of developing diabetes following a COVID-19 infection [33].

The incidence of post-COVID diabetes varies among populations and studies. It appears that certain regions and demographic groups may be more susceptible. Understanding these variations is crucial for tailoring healthcare interventions.

To comprehend the incidence of post-COVID diabetes, it is essential to explore the underlying mechanisms. Several hypotheses have been proposed, including the direct impact of the virus on pancreatic beta cells, immune system dysregulation, and systemic inflammation. Investigating these mechanisms can provide insights into preventive strategies.

The researcher noted the challenge of glucose intolerance, which includes the transient vs. persistent intolerance. In addition to diabetes, glucose intolerance is another metabolic issue observed in post-COVID individuals. While some experience transient intolerance, others develop persistent issues with glucose regulation. This distinction has implications for clinical management and long-term health outcomes. Researchers are exploring whether post-COVID glucose intolerance is reversible. Lifestyle modifications, dietary changes, and exercise interventions may hold promise for managing and potentially reversing glucose intolerance in certain cases. Age and obesity have emerged as significant risk factors for developing post-COVID diabetes and glucose intolerance [34]. Older adults and individuals with a higher body mass index (BMI) appear to be more vulnerable. Genetic factors also play a role in an individual's susceptibility to these metabolic conditions [35]. Understanding the genetic underpinnings can aid in risk stratification. The rising incidence of post-COVID diabetes and glucose intolerance places additional strain on healthcare systems worldwide. It necessitates a reevaluation of resource allocation and preparedness. Prevention becomes a key focus in the face of this growing health concern. Strategies may include promoting a healthy lifestyle, early detection of metabolic changes, and vaccination campaigns. Further, longitudinal studies tracking the health outcomes of individual’s post-COVID are essential. These studies can shed light on the trajectory of metabolic disorders and inform clinical guidelines [36].

As we navigate the post-COVID era, the incidence of diabetes and glucose intolerance in individuals who have recovered from COVID-19 remains a significant concern. Understanding the factors contributing to the development of these metabolic conditions, their prevalence in different populations, and their long-term implications is essential. Addressing the incidence of post-COVID diabetes and glucose intolerance requires a multidisciplinary approach involving healthcare providers, researchers, and public health officials. By doing so, we can better prepare for the challenges posed by these metabolic disorders in the wake of the pandemic.

COVID-19 and obesity

The COVID-19 pandemic has not only brought to light the severe health risks associated with the virus but has also underscored the importance of understanding the various factors that contribute to its severity. Among these factors, obesity has emerged as a significant and concerning comorbidity. This introduction explores the complex relationship between COVID-19 and obesity, shedding light on the implications of obesity in the context of the pandemic.

Examining the existence of a direct association between COVID-19 and obesity

Obesity has long been recognized as a global health concern, but the COVID-19 pandemic has amplified its significance. This article delves into the intricate relationship between obesity and COVID-19, aiming to discern the existence of a direct association between the two. It explores the physiological mechanisms linking obesity to COVID-19 susceptibility and severity, the epidemiological evidence supporting this connection, and the potential implications for public health strategies and clinical management [37]. Additionally, we discuss the challenges posed by obesity in the context of vaccination efforts and the importance of addressing this comorbidity to mitigate the impact of future pandemics. Through a comprehensive examination of the existing literature and research findings, we aim to provide insights into the multifaceted relationship between obesity and COVID-19, shedding light on the urgent need for targeted interventions and public health initiatives to address this critical issue.

Obesity is a global health crisis with far-reaching consequences. The World Health Organization (WHO) defines obesity as "abnormal or excessive fat accumulation that presents a risk to health." [38] It is a multifactorial condition influenced by genetic, environmental, and behavioral factors. The prevalence of obesity has been steadily rising over the past few decades, reaching epidemic proportions. According to the WHO, in 2016, more than 1.9 billion adults worldwide were overweight, with over 650 million of them classified as obese [39]. The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has had a profound impact on global health and has highlighted the critical need to understand the various factors that contribute to the severity and outcomes of the disease. While advanced age and underlying health conditions have been identified as significant risk factors for severe COVID-19, the role of obesity has gained increasing attention.

Physiological mechanisms linking obesity to COVID-19 are well-explained in the literature. To comprehend the association between obesity and COVID-19, it is essential to explore the physiological mechanisms that underlie this connection. Obesity is characterized by chronic low-grade inflammation and dysregulation of the immune system, which can impair the body's ability to respond to infections effectively [40]. Several key factors contribute to the increased susceptibility of obese individuals to respiratory infections, including those caused by viruses like SARS-CoV-2.

Obesity can disrupt the immune response by impairing the function of immune cells, particularly T cells. T cells play a crucial role in recognizing and attacking viruses. In obese individuals, there is often a state of chronic inflammation, which can lead to immune cell dysfunction and exhaustion. This weakened immune response can make obese individuals more susceptible to infections and less capable of mounting an effective defense. Further, obesity is associated with reduced lung function, characterized by decreased lung volume and impaired gas exchange [41]. These respiratory changes can hinder the body's ability to cope with respiratory infections, such as COVID-19. Additionally, obese individuals may have a reduced ability to clear mucus from their airways, providing an environment conducive to viral replication and further complicating respiratory infections. Moreover, adipose tissue, commonly known as fat tissue, is not merely an energy storage site. It also plays a dynamic role in immune regulation and inflammation. Adipose tissue can serve as a reservoir for viruses, including coronaviruses [42]. The presence of the virus in adipose tissue can potentially lead to a prolonged viral shedding period, increasing the risk of transmission to others and the development of severe disease. Obesity often leads to dysregulation of various metabolic factors, including insulin resistance and elevated levels of proinflammatory cytokines. These factors can create an environment conducive to viral replication and may contribute to the excessive inflammation observed in severe cases of COVID-19, often referred to as a "cytokine storm [43]."

Epidemiological evidence

The physiological mechanisms discussed above provide insights into the potential reasons behind the increased vulnerability of obese individuals to severe COVID-19. However, to establish a direct association, epidemiological evidence is crucial. Over the course of the pandemic, numerous studies have examined the relationship between obesity and COVID-19 outcomes, including susceptibility, hospitalization rates, disease severity, and mortality. Several studies have shown that obese individuals may have an elevated risk of contracting SARS-CoV-2 compared to those with a normal body mass index (BMI) [44]. A study published in The Lancet Diabetes and Endocrinology found that the risk of testing positive for COVID-19 increased progressively with increasing BMI [45]. This suggests that obesity may be associated with an increased likelihood of exposure to the virus or a heightened susceptibility to infection. Obesity has been consistently linked to higher rates of hospitalization among COVID-19 patients. A study published in JAMA Internal Medicine reported that obese patients with COVID-19 were more likely to be hospitalized than those with a lower BMI, Hospitalization rates [46].

Evolution of treatment strategies

The COVID-19 pandemic has presented an unprecedented challenge to healthcare systems worldwide. Since the early days of the pandemic, the medical community has been tirelessly working to develop effective treatment strategies to combat the virus and improve patient outcomes. This article delves into the evolving landscape of COVID-19 treatment, tracing the journey from the initial stages of the pandemic to the latest developments [47]. It explores the role of antiviral medications, repurposed drugs, immunomodulators, and vaccines in the fight against COVID-19. Additionally, we discuss the importance of adaptive approaches, clinical trials, and the lessons learned from the global response to the pandemic. Through a comprehensive examination of the evolution of treatment strategies, we aim to provide insights into the dynamic nature of the pandemic response and the ongoing pursuit of effective therapeutic interventions.

A comprehensive review of treatment approaches during the 1st, 2nd, and 3rd COVID-19 waves

The COVID-19 pandemic has unfolded in waves, each characterized by varying degrees of infection rates, viral mutations, and healthcare challenges. As the world grappled with the novel coronavirus, healthcare professionals and researchers swiftly adapted their treatment approaches to address the evolving landscape of the pandemic. This comprehensive review examines the dynamic nature of COVID-19 treatment strategies during the 1st, 2nd, and 3rd waves of the pandemic.

In the 1st wave, in the initial phase of the pandemic, healthcare systems were inundated with patients presenting with a range of symptoms, from mild respiratory issues to severe acute respiratory distress syndrome (ARDS) [48]. Treatment approaches primarily focused on supportive care, including oxygen therapy and mechanical ventilation for critically ill patients. Antiviral drugs such as remdesivir and hydroxychloroquine garnered attention but lacked definitive evidence of efficacy. The repurposing of existing drugs and the exploration of novel therapeutics characterized this phase. Clinical trials played a pivotal role in assessing the safety and effectiveness of potential treatments.

With the emergence of the 2nd wave, the medical community had gained valuable insights from the initial wave's experiences. Clinicians became more adept at managing COVID-19 patients, employing a combination of antiviral medications, corticosteroids, and immunomodulators. Dexamethasone, in particular, showed promise in reducing mortality among severely ill patients. Monoclonal antibody therapies also became a focal point, offering passive immunity to high-risk individuals. Vaccination campaigns began during this phase, marking a critical milestone in the pandemic response [49].

As the 3rd wave unfolded, vaccination efforts gained momentum, providing a glimmer of hope amid the persisting challenges. Multiple vaccines received emergency use authorization, offering protection against severe illness and reducing transmission. Treatment approaches continued to evolve, with a greater emphasis on early intervention, monitoring for emerging variants, and optimizing vaccination distribution. The importance of a multidisciplinary approach, including critical care, pulmonology, infectious disease, and vaccination teams, became evident [50].

Adaptive strategies and future prospects

Throughout these waves, healthcare systems adapted to the shifting demands, refining treatment protocols and enhancing patient care. The integration of telemedicine, remote monitoring, and data-driven decision-making played crucial roles in managing the pandemic's impact. Research into novel therapeutics, including antiviral agents and monoclonal antibodies, continues to explore potential treatments [51]. The experience gained from the pandemic has accelerated scientific collaboration and innovation, paving the way for more robust pandemic preparedness in the future.

Finally, the COVID-19 pandemic has witnessed a dynamic evolution of treatment strategies across its successive waves. From early discoveries to therapeutic advancements and vaccination campaigns, healthcare professionals and researchers have continuously adapted to the challenges posed by the virus. The collaborative efforts of the global healthcare community, coupled with ongoing research and adaptive approaches, hold the promise of better outcomes and enhanced pandemic preparedness in the post-COVID era.

Discussing current government-recommended treatment and management protocols

Effective management of COVID-19 relies on the development and implementation of treatment protocols recommended by governments and health organizations. These protocols serve as guidelines for healthcare professionals and ensure a standardized approach to patient care. In this section, we will delve into the importance and key components of current government-recommended treatment and management protocols for COVID-19.

Government-recommended treatment and management protocols play a crucial role in the response to the COVID-19 pandemic [52]. They provide a structured framework for healthcare providers to deliver care that is evidence-based, consistent, and aligned with the latest scientific knowledge. By following established protocols, healthcare teams can provide consistent care to COVID-19 patients, irrespective of their location or treating facility. This standardization ensures that patients receive the best possible care regardless of where they are treated.

Protocols help in the efficient allocation of healthcare resources such as hospital beds, ventilators, and medications. They guide healthcare providers in determining which patients require hospitalization and which can be managed at home, preventing resource shortages. Protocols are updated based on emerging scientific evidence and clinical experience. This ensures that treatments and interventions are in line with the latest research findings, leading to better patient outcomes.

Key components of treatment protocols

Government-recommended treatment and management protocols for COVID-19 typically encompass several key components:

Patient triage: Protocols begin with guidelines for identifying and triaging COVID-19 patients based on the severity of their symptoms and risk factors. This includes determining which patients require hospitalization intensive care or can be managed at home.

Diagnostic testing: Recommendations for COVID-19 diagnostic testing, including the types of tests (e. g., PCR, antigen) and when to use them, are outlined. Protocols also cover the interpretation of test results.

Pharmacological interventions: Protocols detail the use of antiviral medications, corticosteroids, and other drugs based on the patient's clinical status. They provide dosing guidelines, duration of treatment, and contraindications.

Supportive care: Management of symptoms and complications, such as oxygen therapy, mechanical ventilation, and renal replacement therapy, is an integral part of protocols. These guidelines ensure timely interventions to address patient needs.

Infection prevention and control: Protocols emphasize measures to prevent the spread of the virus within healthcare facilities, including personal protective equipment (PPE) use, isolation precautions, and environmental cleaning.

Vaccination: With the availability of COVID-19 vaccines, protocols provide guidance on vaccine administration, prioritization, and monitoring for adverse effects.

Monitoring and follow-up: Protocols outline the frequency and types of patient assessments required during hospitalization or home care. They also address criteria for patient discharge and follow-up care [52].

Table 1: Analysis of key topics and subtopics in post-COVID-19 research

S. No. Main topic Subtopic Aspect for analysis Key findings
1 Diabetes and glucose intolerance Incidence in the Post-COVID Era Prevalence Increased incidence in the post-COVID period
    Risk Factors Identification of high-risk groups
    Management Strategies for diabetes control
    Impact Effects on overall public health
2 COVID-19 and Obesity Direct Association with Obesity Epidemiological Evidence Studies linking COVID-19 and obesity
    Underlying Mechanisms How obesity influences COVID-19 outcomes
    Public Health Implications Strategies for obesity management
3 Treatment Strategies Review During the 1st, 2nd, and 3rd COVID-19 Waves Therapeutic Approaches Evolution of treatment approaches
    Clinical Outcomes Impact on patient outcomes
    Lessons Learned Insights from each pandemic wave
    Current Protocols Government-recommended guidelines

Adaptability and continual updates

One of the challenges in managing COVID-19 has been the dynamic nature of the virus and the emergence of new variants. Government-recommended treatment protocols must be adaptable and regularly updated to reflect the evolving scientific understanding of the disease. Healthcare authorities collaborate with experts and researchers to review and revise protocols as new information becomes available.

Lastly government-recommended treatment and management protocols are instrumental in guiding healthcare professionals in the effective care of COVID-19 patients. These protocols standardize care, optimize resource utilization, and ensure evidence-based practice. They encompass various components, from patient triage to infection prevention, and are adaptable to accommodate the changing landscape of the pandemic. As our understanding of COVID-19 continues to evolve, these protocols will remain crucial tools in the fight against the virus, enabling healthcare systems to respond effectively and save lives.

In the Indian scenario, the review of post-COVID-19 infections is of paramount importance. With a diverse population and varying healthcare infrastructure, understanding the multifaceted aspects of post-COVID symptoms, their association with conditions like diabetes and obesity, and the evolution of treatment strategies is crucial for effectively managing the aftermath of the pandemic in the country. This analysis can inform healthcare professionals and policymakers in tailoring strategies to address the unique challenges posed by post-COVID-19 complications in India.

CONCLUSION

In conclusion, this comprehensive review has delved into the multifaceted landscape of post-COVID-19 infections, shedding light on common and rare symptomatology, exploring the association with diabetes and glucose intolerance, examining the links between COVID-19 and obesity, and tracing the evolution of treatment strategies through the pandemic's waves. As we continue to navigate the challenges posed by post-COVID-19 conditions, this review serves as a valuable resource for understanding and addressing the diverse and evolving aspects of this complex health issue.

FUNDING

Nil

AUTHOR CONTRIBUTION

All the work have been carried out by me.

CONFLICTS OF INTERESTS

Declared none

REFERENCES

  1. Pollard CA, Morran MP, Nestor Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020 Nov 19;52(11):549-57. doi: 10.1152/physiolgenomics.00089.2020, PMID 32991251.

  2. Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021 Jun 23;12:698169. doi: 10.3389/fmicb.2021.698169, PMID 34248921.

  3. Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterization of post‐COVID‐19 manifestations. Int J Clin Pract. 2021 Mar;75(3):e13746. doi: 10.1111/ijcp.13746, PMID 32991035.

  4. Xie L, Zhang Z, Wang Q, Chen Y, Lu D, Wu W. COVID-19 and diabetes: a comprehensive review of angiotensin-converting enzyme 2, mutual effects and pharmacotherapy. Front Endocrinol. 2021 Nov 19;12:772865. doi: 10.3389/fendo.2021.772865, PMID 34867819.

  5. Katsoulis M, Pasea L, Lai AG, Dobson RJB, Denaxas S, Hemingway H. Obesity during the COVID-19 pandemic: both cause of high risk and the potential effect of lockdown? A population-based electronic health record study. Public Health. 2021 Feb 1;191:41-7. doi: 10.1016/j.puhe.2020.12.003, PMID 33497994.

  6. Organization for Economic Co-operation and Development. The territorial impact of COVID-19: managing the crisis and recovery across levels of government. OECD Publishing; 2021.

  7. Sherif ZA, Gomez CR, Connors TJ, Henrich TJ, Reeves WB, Recover Mechanistic Pathway Task Force. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). eLife. 2023 Mar 22;12:e86002. doi: 10.7554/eLife.86002, PMID 36947108.

  8. Joli J, Buck P, Zipfel S, Stengel A. Post-COVID-19 fatigue: a systematic review. Front Psychiatry. 2022 Aug 11;13:947973. doi: 10.3389/fpsyt.2022.947973, PMID 36032234.

  9. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601-15. doi: 10.1038/s41591-021-01283-z, PMID 33753937.

  10. Ahmed I, Mustafaoglu R, Yeldan I, Yasaci Z, Erhan B. Effect of pulmonary rehabilitation approaches on dyspnea, exercise capacity, fatigue, lung functions, and quality of life in patients with COVID-19: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2022 Jul 29;103(10):2051-62. doi: 10.1016/j.apmr.2022.06.007, PMID 35908659.

  11. Melendez Oliva E, Martinez Pozas O, Cuenca Zaldivar JN, Villafane JH, Jimenez Ortega L, Sanchez Romero EA. Efficacy of pulmonary rehabilitation in post-COVID-19: a systematic review and meta-analysis. Biomedicines. 2023 Aug 7;11(8):2213. doi: 10.3390/biomedicines11082213, PMID 37626710.

  12. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6 mo retrospective cohort study of 273,618 survivors of COVID-19. PLOS Med. 2021 Sep 28;18(9):e1003773. doi: 10.1371/journal.pmed.1003773, PMID 34582441.

  13. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022 Mar 1;101:93-135. doi: 10.1016/j.bbi.2021.12.020, PMID 34973396.

  14. Rabaiotti P, Ciraci C, Donelli D, Oggioni C, Rizzi B, Savi F. Effects of multidisciplinary rehabilitation enhanced with neuropsychological treatment on post-acute SARS-CoV-2 cognitive impairment (brain fog): an observational study. Brain Sci. 2023 May 12;13(5):791. doi: 10.3390/brainsci13050791, PMID 37239263.

  15. Raman B, Bluemke DA, Luscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022 Mar 14;43(11):1157-72. doi: 10.1093/eurheartj/ehac031, PMID 35176758.

  16. Hasan LK, Deadwiler B, Haratian A, Bolia IK, Weber AE, Petrigliano FA. Effects of COVID-19 on the musculoskeletal system: clinician’s guide. Orthop Res Rev. 2021 Sep 21;13:141-50. doi: 10.2147/ORR.S321884, PMID 34584465.

  17. Groff A, Kavanaugh M, Ramgobin D, McClafferty B, Aggarwal CS, Golamari R. Gastrointestinal manifestations of COVID-19: a review of what we know. Ochsner J. 2021 Jun 20;21(2):177-80. doi: 10.31486/toj.20.0086, PMID 34239378.

  18. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133-46. doi: 10.1038/s41579-022-00846-2, PMID 36639608.

  19. Sequeria Rodriguez P, Santana Ortiz R, Ortiz Hernandez E. Late onset and persistent parosmia and dysgeusia as a neurosensorial complication by the SARS virus COV 2. Otolaryngol Case Rep. 2023 Mar 1;26:100510. doi: 10.1016/j.xocr.2023.100510, PMID 36691459.

  20. Pedrosa AL, Bitencourt L, Froes ACF, Cazumba MLB, Campos RGB, de Brito SBCS. Emotional, behavioral, and psychological impact of the COVID-19 pandemic. Front Psychol. 2020 Oct 2;11:566212. doi: 10.3389/fpsyg.2020.566212, PMID 33117234.

  21. Coronavirus disease (COVID-19): post COVID-19 condition. Who. Int. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition. [Last accessed on 29 Sep 2023]

  22. Levine RL. Addressing the long-term effects of COVID-19. JAMA. 2022 Sep 6;328(9):823-4. doi: 10.1001/jama.2022.14089, PMID 35921084.

  23. Kaafarani HM, Weiser M, Chen W. COVID-19: gastrointestinal symptoms and complications; 2023.

  24. Kariyawasam JC, Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL. Gastrointestinal manifestations in COVID-19. Trans R Soc Trop Med Hyg. 2021 Dec;115(12):1362-88. doi: 10.1093/trstmh/trab042, PMID 33728439.

  25. Moghimi N, Di Napoli M, Biller J, Siegler JE, Shekhar R, McCullough LD. The neurological manifestations of post-acute sequelae of SARS-CoV-2 infection. Curr Neurol Neurosci Rep. 2021 Sep;21(9):44. doi: 10.1007/s11910-021-01130-1, PMID 34181102.

  26. Korchut A, Rejdak K. Late neurological consequences of SARS-CoV-2 infection: new challenges for the neurologist. Front Neurosci. 2023 Feb 9;17:1004957. doi: 10.3389/fnins.2023.1004957, PMID 36845421.

  27. Panda M, Dash S, Behera B, Sil A. Dermatological manifestations associated with COVID-19 infection. Indian J Dermatol. 2021 May;66(3):237-45. doi: 10.4103/ijd.ijd_464_21, PMID 34446946.

  28. Hadeler E, Morrison BW, Tosti A. A review of nail findings associated with COVID‐19 infection. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e699-709. doi: 10.1111/jdv.17448, PMID 34131957.

  29. Tomidokoro D, Hiroi Y. Cardiovascular implications of the COVID-19 pandemic. J Cardiol. 2022 Apr 1;79(4):460-7. doi: 10.1016/j.jjcc.2021.09.010, PMID 34563439.

  30. Fu Y, Zhang TQ, Dong CJ, Xu YS, Dong HQ, Ning J. Clinical characteristics of 14 pediatric mycoplasma pneumoniae pneumonia associated thrombosis: a retrospective study. BMC Cardiovasc Disord. 2023;23(1):1. doi: 10.1186/s12872-022-03030-9, PMID 36600223.

  31. Xiong J, Lipsitz O, Nasri F, Lui LMW, Gill H, Phan L. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020 Dec 1;277:55-64. doi: 10.1016/j.jad.2020.08.001, PMID 32799105.

  32. Aluganti Narasimhulu C, Singla DK. Mechanisms of COVID-19 pathogenesis in diabetes. Am J Physiol Heart Circ Physiol. 2022 Sep 1;323(3):H403-20. doi: 10.1152/ajpheart.00204.2022, PMID 35776683.

  33. Chourasia P, Goyal L, Kansal D, Roy S, Singh R, Mahata I. Risk of new-onset diabetes mellitus as a post-COVID-19 condition and possible mechanisms: a scoping review. J Clin Med. 2023 Feb 1;12(3):1159. doi: 10.3390/jcm12031159, PMID 36769807.

  34. Rizvi AA, Kathuria A, Al Mahmeed W, Al-Rasadi K, Al-Alawi K, Banach M. Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complications. 2022 Oct 6;36(11):108336. doi: 10.1016/j.jdiacomp.2022.108336, PMID 36228563.

  35. Malik VS, Ravindra K, Attri SV, Bhadada SK, Singh M. Higher body mass index is an important risk factor in COVID-19 patients: a systematic review and meta-analysis. Environ Sci Pollut Res Int. 2020 Nov;27(33):42115-23. doi: 10.1007/s11356-020-10132-4, PMID 32710359.

  36. Abumayyaleh M, Nunez Gil IJ, Viana LLamas MC, Raposeiras Roubin S, Romero R, Alfonso Rodriguez E, Uribarri A, Feltes G, Becerra Munoz VM, Santoro F, Pepe M. Post-COVID-19 syndrome and diabetes mellitus: a propensity-matched analysis of the international HOPE-II COVID-19 registry. Frontiers in Endocrinology. 2023 May 16;14:1167087.

  37. Yang J, Ma Z, Lei Y. A meta-analysis of the association between obesity and COVID-19. Epidemiol Infect. 2020;149:e11. doi: 10.1017/S0950268820003027, PMID 33349290.

  38. Obesity. Who. Int. Available from: https://www.who.int/health-topics/obesity. [Last accessed on 29 Sep 2023]

  39. World Obesity Day. Africa Health Organisation; 2020. Available from: https://aho.org/events/world-obesity-day. [Last accessed on 29 Sep 2023]

  40. Khanna D, Khanna S, Khanna P, Kahar P, Patel BM. Obesity: a chronic low-grade inflammation and its markers. Cureus. 2022 Feb 28;14(2):e22711. doi: 10.7759/cureus.22711, PMID 35386146.

  41. De Heredia FP, Gomez Martinez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc. 2012 May;71(2):332-8. doi: 10.1017/S0029665112000092, PMID 22429824.

  42. Subbarao K, Mahanty S. Respiratory virus infections: understanding COVID-19. Immunity. 2020 Jun 16;52(6):905-9. doi: 10.1016/j.immuni.2020.05.004, PMID 32497522.

  43. Hu B, Huang S, Yin L. The cytokine storm and COVID‐19. J Med Virol. 2021 Jan;93(1):250-6. doi: 10.1002/jmv.26232, PMID 32592501.

  44. Sharma JR, Yadav UCS. COVID-19 severity in obese patients: potential mechanisms and molecular targets for clinical intervention. Obes Res Clin Pract. 2021 Mar 1;15(2):163-71. doi: 10.1016/j.orcp.2021.01.004, PMID 33509701.

  45. Gao M, Piernas C, Astbury NM, Hippisley Cox J, O’Rahilly S, Aveyard P. Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021 Jun 1;9(6):350-9. doi: 10.1016/S2213-8587(21)00089-9, PMID 33932335.

  46. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020 May 26;323(20):2052-9. doi: 10.1001/jama.2020.6775, PMID 32320003.

  47. Feuillet V, Canard B, Trautmann A. Combining antivirals and immunomodulators to fight COVID-19. Trends Immunol. 2021 Jan 1;42(1):31-44. doi: 10.1016/j.it.2020.11.003, PMID 33281063.

  48. Gibson PG, Qin L, Puah SH. COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐COVID‐19 ARDS. Med J Aust. 2020 Jul;213(2):54-56.e1. doi: 10.5694/mja2.50674, PMID 32572965.

  49. Tendulkar P, Pandey P, Panda PK, Bhadoria AS, Kulshreshtha P, Mishra M. Comparative study between the first and second wave of COVID-19 deaths in India: A Single Center Study. Cureus. 2023 Apr 12;15(4):e37472. doi: 10.7759/cureus.37472, PMID 37187656.

  50. Baig R, Mateen MA, Aborode AT, Novman S, Abdul Matheen IA, Siddiqui OS. Third wave in India and an update on vaccination: a short communication. Ann Med Surg (Lond). 2022 Mar 1;75:103414. doi: 10.1016/j.amsu.2022.103414, PMID 35261767.

  51. Haleem A, Javaid M, Singh RP, Suman R. Telemedicine for healthcare: capabilities, features, barriers, and applications. Sens Int. 2021 Jan 1;2:100117. doi: 10.1016/j.sintl.2021.100117, PMID 34806053.

  52. Mohfw G. Clinical management protocol for COVID-19 (in adults). Version 6. 2023;24:21.